IQ-AI finances Phase I trial evaluating Gallium Maltolate in treatment of Glioblastoma Multiforme Imaging Biometrics’ IB Clinic software used to assess performance IQ-AI Limited (LON:IQAI) — IQ-AI commits to funding a phase I clinical trial to evaluate the safety and efficacy of Gallium Maltolate (GaM) in the treatment of Glioblastoma Multiforme (GBM). Its Imaging Biometrics

IQ-AI’s Imaging Biometrics’ IB Neuro brain tumor software named part of standard imaging protocol IQ-AI Limited (LON:IQAI) — The investment firm explains how IB’s brain tumour imaging software benefits patients and their treatment teams, and why IB Neuro was solely included as the image post-processing component of the new standardised imaging protocol for brain tumours.